Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Appoints New Global Generics Head Amid Massive Integration

Executive Summary

Just months after Teva closed the $40.5bn acquisition of Allergan Generics, the company said the man expected to lead the integration, Siggi Olafsson, will step down and be succeeded by Dipankar Bhattacharjee.

You may also be interested in...



End Of Schultz Era Looms For Teva

Teva is expecting to have a new CEO by the end of next year, after current leader Kåre Schultz indicated that he was unlikely to renew his contract. The president and chief executive has overseen an eventful and transformative period for the Israeli firm.

Teva Hits Pause On Business Development, Even As Some Deals Stumble

Teva CEO Erez Vigodman said the company will step away from business development for the “foreseeable future” while it digests the acquisition of Allergan’s generic drug business.

Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches

The world’s generic drug leader has cemented its leadership position for the foreseeable future with the acquisition of Allergan’s generics business. Management outlined how it plans to grow the combined business by taking advantage of its size during an investor briefing.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB001655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel